-
1
-
-
84957878858
-
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
-
Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18(3):203-16.
-
(2016)
Diabetes Obes Metab
, vol.18
, Issue.3
, pp. 203-216
-
-
Nauck, M.1
-
2
-
-
59049087723
-
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
-
Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA. 2009;106(4):1285-90.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, Issue.4
, pp. 1285-1290
-
-
Li, Y.1
Perry, T.2
Kindy, M.S.3
Harvey, B.K.4
Tweedie, D.5
Holloway, H.W.6
Powers, K.7
Shen, H.8
Egan, J.M.9
Sambamurti, K.10
-
3
-
-
84875438002
-
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride
-
Darsalia V, Ortsater H, Olverling A, Darlof E, Wolbert P, Nystrom T, Klein T, Sjoholm A, Patrone C. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2013;62(4):1289-96.
-
(2013)
Diabetes
, vol.62
, Issue.4
, pp. 1289-1296
-
-
Darsalia, V.1
Ortsater, H.2
Olverling, A.3
Darlof, E.4
Wolbert, P.5
Nystrom, T.6
Klein, T.7
Sjoholm, A.8
Patrone, C.9
-
4
-
-
85042442686
-
Glucagon-like receptor 1 agonists and DPP-4 inhibitors: anti-diabetic drugs with anti-stroke potential
-
Darsalia V, Klein T, Nystrom T, Patrone C. Glucagon-like receptor 1 agonists and DPP-4 inhibitors: anti-diabetic drugs with anti-stroke potential. Neuropharmacology. 2017. https://doi.org/10.1016/j.neuropharm.2017.08.022.
-
(2017)
Neuropharmacology
-
-
Darsalia, V.1
Klein, T.2
Nystrom, T.3
Patrone, C.4
-
5
-
-
85029679644
-
Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
-
Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849-70.
-
(2017)
Circulation
, vol.136
, Issue.9
, pp. 849-870
-
-
Nauck, M.A.1
Meier, J.J.2
Cavender, M.A.3
Abd El Aziz, M.4
Drucker, D.J.5
-
6
-
-
85042432121
-
Effects of glucose-lowering agents on ischemic stroke
-
Avgerinos K, Tziomalos K. Effects of glucose-lowering agents on ischemic stroke. World J Diabetes. 2017;8(6):270-7.
-
(2017)
World J Diabetes
, vol.8
, Issue.6
, pp. 270-277
-
-
Avgerinos, K.1
Tziomalos, K.2
-
7
-
-
84969506808
-
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
-
Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;5:CD012204.
-
(2017)
Cochrane Database Syst Rev
, vol.5
-
-
Hemmingsen, B.1
Sonne, D.P.2
Metzendorf, M.I.3
Richter, B.4
-
8
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22.
-
(2016)
N Engl J Med
, vol.375
, Issue.4
, pp. 311-322
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
Kristensen, P.4
Mann, J.F.5
Nauck, M.A.6
Nissen, S.E.7
Pocock, S.8
Poulter, N.R.9
Ravn, L.S.10
-
9
-
-
84994813253
-
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
-
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44.
-
(2016)
N Engl J Med
, vol.375
, pp. 1834-1844
-
-
Marso, S.P.1
Bain, S.C.2
Consoli, A.3
Eliaschewitz, F.G.4
Jodar, E.5
Leiter, L.A.6
Lingvay, I.7
Rosenstock, J.8
Seufert, J.9
Warren, M.L.10
-
10
-
-
85030448557
-
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
-
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228-39.
-
(2017)
N Engl J Med
, vol.377
, Issue.13
, pp. 1228-1239
-
-
Holman, R.R.1
Bethel, M.A.2
Mentz, R.J.3
Thompson, V.P.4
Lokhnygina, Y.5
Buse, J.B.6
Chan, J.C.7
Choi, J.8
Gustavson, S.M.9
Iqbal, N.10
-
11
-
-
85029218795
-
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
-
Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD, Lai E. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):112.
-
(2017)
Cardiovasc Diabetol
, vol.16
, Issue.1
, pp. 112
-
-
Gantz, I.1
Chen, M.2
Suryawanshi, S.3
Ntabadde, C.4
Shah, S.5
O'Neill, E.A.6
Engel, S.S.7
Kaufman, K.D.8
Lai, E.9
-
12
-
-
85014351364
-
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
-
Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, Li M, Zhang S, Jia J, Shao S, et al. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol. 2017;16(1):31.
-
(2017)
Cardiovasc Diabetol
, vol.16
, Issue.1
, pp. 31
-
-
Zhang, Z.1
Chen, X.2
Lu, P.3
Zhang, J.4
Xu, Y.5
He, W.6
Li, M.7
Zhang, S.8
Jia, J.9
Shao, S.10
-
13
-
-
85044600598
-
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
-
Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2017. https://doi.org/10.1016/S2213-8587(17)30412-6.
-
(2017)
Lancet Diabetes Endocrinol
-
-
Bethel, M.A.1
Patel, R.A.2
Merrill, P.3
Lokhnygina, Y.4
Buse, J.B.5
Mentz, R.J.6
Pagidipati, N.J.7
Chan, J.C.8
Gustavson, S.M.9
Iqbal, N.10
-
14
-
-
85007489154
-
Dipeptidyl peptidase-4 inhibitors and protection against stroke: a systematic review and meta-analysis
-
Barkas F, Elisaf M, Tsimihodimos V, Milionis H. Dipeptidyl peptidase-4 inhibitors and protection against stroke: a systematic review and meta-analysis. Diabetes Metab. 2017;43(1):1-8.
-
(2017)
Diabetes Metab
, vol.43
, Issue.1
, pp. 1-8
-
-
Barkas, F.1
Elisaf, M.2
Tsimihodimos, V.3
Milionis, H.4
-
15
-
-
85042450975
-
Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke
-
Li YR, Tsai SS, Chen DY, Chen ST, Sun JH, Chang HY, Liou MJ, Chen TH. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke. Cardiovasc Diabetol. 2018;17(1):2.
-
(2018)
Cardiovasc Diabetol
, vol.17
, Issue.1
, pp. 2
-
-
Li, Y.R.1
Tsai, S.S.2
Chen, D.Y.3
Chen, S.T.4
Sun, J.H.5
Chang, H.Y.6
Liou, M.J.7
Chen, T.H.8
-
16
-
-
84863560602
-
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
-
Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, Jorgensen E, Helqvist S, Saunamaki K, Clemmensen P, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491-9.
-
(2012)
Eur Heart J
, vol.33
, Issue.12
, pp. 1491-1499
-
-
Lonborg, J.1
Vejlstrup, N.2
Kelbaek, H.3
Botker, H.E.4
Kim, W.Y.5
Mathiasen, A.B.6
Jorgensen, E.7
Helqvist, S.8
Saunamaki, K.9
Clemmensen, P.10
-
17
-
-
85028049108
-
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
-
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664-75.
-
(2017)
Lancet
, vol.390
, pp. 1664-1675
-
-
Athauda, D.1
Maclagan, K.2
Skene, S.S.3
Bajwa-Joseph, M.4
Letchford, D.5
Chowdhury, K.6
Hibbert, S.7
Budnik, N.8
Zampedri, L.9
Dickson, J.10
-
18
-
-
85030707291
-
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
-
Athauda D, Foltynie T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology. 2017. https://doi.org/10.1016/j.neuropharm.2017.09.023.
-
(2017)
Neuropharmacology
-
-
Athauda, D.1
Foltynie, T.2
-
19
-
-
84856830094
-
Diabetes, hyperglycaemia, and acute ischaemic stroke
-
Luitse MJ, Biessels GJ, Rutten GE, Kappelle LJ. Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol. 2012;11(3):261-71.
-
(2012)
Lancet Neurol
, vol.11
, Issue.3
, pp. 261-271
-
-
Luitse, M.J.1
Biessels, G.J.2
Rutten, G.E.3
Kappelle, L.J.4
-
20
-
-
84922274240
-
Changes in functional outcome over the first year after stroke: an observational study from the Swedish stroke register
-
Ullberg T, Zia E, Petersson J, Norrving B. Changes in functional outcome over the first year after stroke: an observational study from the Swedish stroke register. Stroke. 2015;46(2):389-94.
-
(2015)
Stroke
, vol.46
, Issue.2
, pp. 389-394
-
-
Ullberg, T.1
Zia, E.2
Petersson, J.3
Norrving, B.4
|